{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:56:45Z","timestamp":1790668605563,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ropeginterferon alfa\u20102b is a new\u2010generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics\u2013pharmacodynamics (PopPK\u2010PD) and delineate exposure\u2013response (E\u2010R) relationships in ET. A population PK model was constructed utilizing aggregated data from five clinical trials, encompassing a study population of Asian and Caucasian patients with ET and healthy volunteers. A sequential modeling strategy was employed to evaluate the PK\u2010PD with respect to key hematologic markers including platelet and white blood cell counts. Hematologic changes were effectively modeled using sigmoidal indirect\u2010response models. Individual exposure metrics were subsequently simulated by a target\u2010mediated drug disposition model and then applied in E\u2010R analyses for reductions in the allele burden of MPN driver mutations\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F and\n                    <jats:italic>CALR<\/jats:italic>\n                    , and safety outcomes. Simulations indicated no significant disparities between ethnicities in ropeginterferon alfa\u20102b exposure or the extent of hematologic response. A correlation was observed between drug exposure and a decrease in\n                    <jats:italic>JAK2<\/jats:italic>\n                    V617F allele burden at 6 and 12 months of treatment. Exposure\u2013safety assessments identified a risk of exposure\u2010related adverse events, including reversible anemia. Taken together, the data provided a solid PK\u2010PD framework and insights into the E\u2010R relationships for ropeginterferon alfa\u20102b in the treatment of ET.\n                  <\/jats:p>","DOI":"10.1002\/jcph.70258","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:24:45Z","timestamp":1790666685000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exposure\u2013Response Analyses of Ropeginterferon Alfa\u20102b in Essential Thrombocythemia"],"prefix":"10.1002","volume":"66","author":[{"given":"Albert","family":"Qin","sequence":"first","affiliation":[{"name":"Medical Research &amp; Clinical Operations PharmaEssentia Corporation  Taipei 115 Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[{"name":"Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Pharmaron Clinical Services Co., Ltd  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-4489","authenticated-orcid":false,"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology National Clinical Research Centre for Blood Diseases Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital Zhejiang University School of Medicine  Hangzhou Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Medicine School of Clinical Medicine LKS Faculty of Medicine the University of Hong Kong  Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2106-3698","authenticated-orcid":false,"given":"Brandi N","family":"Reeves","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Medicine Blood Research Center Lineberger Comprehensive Cancer Center The University of North Carolina at Chapel Hill  Chapel Hill NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas El","family":"Chaer","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Department of Medicine The University of Virginia  Charlottesville VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology University of Yamanashi Chuo\u2010shi Yamanashi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[{"name":"PharmaEssentia Japan KK  Tokyo Japan"},{"name":"Department of Haematology Juntendo University School of Medicine  Bunkyo\u2010ku Tokyo Japan"},{"name":"Department of Advanced Hematology Juntendo University Graduate School of Medicine Bunkyo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Abu\u2010Zeinah","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Weill Cornell Medicine  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Division of Hematology Diabetes and Endocrinology Department of Internal Medicine Faculty of Medicine University of Miyazaki Miyazaki\u2010city Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleh","family":"Zagrijtschuk","sequence":"additional","affiliation":[{"name":"PharmaEssentia USA  Burlington MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Sato","sequence":"additional","affiliation":[{"name":"PharmaEssentia Japan KK  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxiang","family":"Wu","sequence":"additional","affiliation":[{"name":"PharmaEssentia Biotech (Beijing) Limited  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[{"name":"Pharmaron Clinical Services Co., Ltd  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Su","sequence":"additional","affiliation":[{"name":"Pharmaron Clinical Services Co., Ltd  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Gao","sequence":"additional","affiliation":[{"name":"Pharmaron Clinical Services Co., Ltd  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cui","sequence":"additional","affiliation":[{"name":"Pharmaron Clinical Services Co., Ltd  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology National Clinical Research Centre for Blood Diseases Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A","family":"Mesa","sequence":"additional","affiliation":[{"name":"Atrium Health, Levine Cancer Institute; Cancer Programs Wake Forest University School of Medicine  Charlotte NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi A","year":"2024","journal-title":"Am J Hematol"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.hoc.2020.12.006","article-title":"Quality of life in myeloproliferative neoplasms: symptoms and management implications","volume":"35","author":"Mesa R","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","DOI":"10.1177\/2634853520978210","article-title":"The essential thrombocythemia in 2020: what we know and where we still have to dig deep","volume":"13","author":"Accurso V","year":"2020","journal-title":"Clin Med Insights Blood Disord"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/labmed\/lmac074","article-title":"Essential thrombocythemia and post\u2010essential thrombocythemia myelofibrosis: updates on diagnosis, clinical aspects, and management","volume":"54","author":"Puglianini OC","year":"2023","journal-title":"Lab Med"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The myeloproliferative neoplasm symptom assessment form (MPN\u2010SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber R","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.2024.25349","article-title":"Essential thrombocythemia: a review","volume":"333","author":"Tefferi A","year":"2025","journal-title":"JAMA"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/16078454.2022.2105582","article-title":"Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance","volume":"27","author":"Chiaranairungrot K","year":"2022","journal-title":"Hematology"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00277-019-03654-6","article-title":"Polycythemia vera and hydroxyurea resistance\/intolerance: a monocentric retrospective analysis","volume":"98","author":"Demuynck T","year":"2019","journal-title":"Ann. Hematol."},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.21360","article-title":"Long\u2010term follow\u2010up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy","volume":"84","author":"Palandri F","year":"2009","journal-title":"Am J Hematol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.3109\/10428194.2014.893310","article-title":"Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory\/resistant to hydroxyurea","volume":"55","author":"Sever M","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1080\/14740338.2021.1945032","article-title":"A review of hydroxyurea\u2010related cutaneous adverse events","volume":"20","author":"Griesshammer M","year":"2021","journal-title":"Expert Opinion on Drug Safety"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.25294","article-title":"Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide","volume":"94","author":"Tefferi A","year":"2019","journal-title":"Am J Hematol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa\u20102a in patients with essential thrombocythaemia or polycythaemia vera: a post\u2010hoc, median 83 month follow\u2010up of an open\u2010label, phase 2 trial","volume":"4","author":"Masarova L","year":"2017","journal-title":"Lancet Haematol"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera\u2010a systematic review and meta\u2010analysis","volume":"35","author":"Bewersdorf JP","year":"2021","journal-title":"Leukemia"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241229588","article-title":"Interferons in the treatment of myeloproliferative neoplasms","volume":"15","author":"Vachhani P","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1073\/pnas.95.24.14411","article-title":"Interferon\u2010beta gene therapy inhibits tumor formation and causes regression of established tumors in immune\u2010deficient mice","volume":"95","author":"Qin XQ","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1089\/10799900260442511","article-title":"Direct evidence that IFN\u2010beta functions as a tumor\u2010suppressor protein","volume":"22","author":"Kaynor C","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1173467","article-title":"An anti\u2010cancer surveillance by the interplay between interferon\u2010beta and retinoblastoma protein RB1","volume":"13","author":"Qin A","year":"2023","journal-title":"Front Oncol"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1080\/14796694.2024.2402649","article-title":"A plain language summary about a cell cycle\u2010based, new surveillance mechanism against cancer","volume":"20","author":"Qin A","year":"2024","journal-title":"Future Oncol"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon\u2010alpha for treating polycythemia vera yields improved myelofibrosis\u2010free and overall survival","volume":"35","author":"Abu\u2010Zeinah G","year":"2021","journal-title":"Leukemia"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","article-title":"Event\u2010free survival in patients with polycythemia vera treated with ropeginterferon alfa\u20102b versus best available treatment","volume":"37","author":"Gisslinger H","year":"2023","journal-title":"Leukemia"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-025-02545-2","article-title":"Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera","volume":"39","author":"Beauverd Y","year":"2025","journal-title":"Leukemia"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon\u2010\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas J","year":"2022","journal-title":"Blood"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa\u20102a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub A","year":"2019","journal-title":"Blood"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2352-3026(25)00264-9","article-title":"Ropeginterferon alfa\u20102b in hydroxyurea\u2010intolerant or hydroxyurea\u2010refractory essential thrombocythaemia (SURPASS ET): a multicentre, open\u2010label, randomised, active\u2010controlled, phase 3 study","volume":"12","author":"Mesa R","year":"2025","journal-title":"Lancet Haematol"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2217\/fon-2022-0596","article-title":"SURPASS\u2010ET: phase III study of ropeginterferon alfa\u20102b versus anagrelide as second\u2010line therapy in essential thrombocythemia","volume":"18","author":"Verstovsek S","year":"2022","journal-title":"Future Oncol"},{"key":"e_1_2_9_28_1","unstructured":"FDA news release: FDA approves treatment for rare blood disease. Accessed December 21 2021.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010treatment\u2010rare\u2010blood\u2010disease."},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/bcp.16043","article-title":"Exposure\u2010efficacy and exposure\u2010safety analyses of ropeginterferon alfa\u20102b treatment in patients with polycythaemia vera","volume":"90","author":"Qin A","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70109","article-title":"Population pharmacokinetics\u2010pharmacodynamics and exposure\u2010response of ropeginterferon alfa\u20102b in Chinese and Japanese patients with polycythemia vera","volume":"13","author":"Qin A","year":"2025","journal-title":"Pharmacol Res Perspect"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2015.61.6474","article-title":"Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F","volume":"33","author":"Stein BL","year":"2015","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison CN","year":"2023","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.2022017697","article-title":"JAK2 V617F allele burden in polycythemia vera: burden of proof","volume":"141","author":"Moliterno AR","year":"2023","journal-title":"Blood"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70137","article-title":"Event\u2010free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa\u20102b or hydroxyurea\/best available therapy (PROUD\u2010PV\/CONTINUATION\u2010PV)","volume":"9","author":"Kiladjian JJ","year":"2025","journal-title":"Hemasphere"},{"key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa\u20102b versus standard therapy for polycythaemia vera (PROUD\u2010PV and CONTINUATION\u2010PV): a randomised, non\u2010inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger H","year":"2020","journal-title":"Lancet Haematol"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21593","article-title":"Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia","volume":"85","author":"De Stefano V","year":"2010","journal-title":"Am J Hematol"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2023020232","article-title":"Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analyses from the REVEAL study","volume":"143","author":"Gerds AT","year":"2024","journal-title":"Blood"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO\u2010defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_39_1","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/bcp.15176","article-title":"Novel long\u2010acting ropeginterferon alfa\u20102b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial","volume":"88","author":"Huang Y\u2010W","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_9_40_1","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1007\/s12325-021-01863-y","article-title":"Pharmacokinetics and pharmacodynamics of novel long\u2010acting ropeginterferon alfa\u20102b in healthy Chinese subjects","volume":"38","author":"Huang Y\u2010W","year":"2021","journal-title":"Adv Thera"},{"key":"e_1_2_9_41_1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","article-title":"Pharmacokinetics and pharmacodynamics of ropeginterferon alfa\u20102b in healthy Japanese and Caucasian subjects after single subcutaneous administration","volume":"41","author":"Miyachi N","year":"2021","journal-title":"Clin Drug Investig"},{"key":"e_1_2_9_42_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1548590","article-title":"A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa\u20102b\u2010njft in patients with essential thrombocythemia in the US and Canada: EXCEED\u2010ET trial","volume":"12","author":"Masarova L","year":"2025","journal-title":"Front Med"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.673492","article-title":"Population pharmacokinetics of ropeginterferon alfa\u20102b: a comparison between healthy Caucasian and Chinese subjects","volume":"12","author":"Zhu M","year":"2021","journal-title":"Front Pharmacol"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12185-014-1721-9","article-title":"Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia","volume":"101","author":"Shirane S","year":"2015","journal-title":"Int J Hematol"},{"key":"e_1_2_9_45_1","first-page":"150","article-title":"The impact of JAK2V617F mutation on Philadelphia\u2010negative myeloproliferative neoplasms","volume":"52","author":"\u015eahin E","year":"2022","journal-title":"Turk J Med Sci"},{"key":"e_1_2_9_46_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target\u2010mediated drug disposition","volume":"28","author":"Mager DE","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"e_1_2_9_47_1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11095-010-0098-6","article-title":"Interspecies scaling of receptor\u2010mediated pharmacokinetics and pharmacodynamics of type I interferons","volume":"27","author":"Kagan L","year":"2010","journal-title":"Pharmaceutical Res"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70258","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:24:52Z","timestamp":1790666692000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/jcph.70258"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70258","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"2026-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70258"}}